These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21844923)

  • 21. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
    Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
    Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
    Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
    World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
    Yaghoobi M; Padol S; Yuan Y; Hunt RH
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):583-90. PubMed ID: 20061959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M; Wu J; Perez MC
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection.
    Vakil NB; Traxler BM; Levine D
    Am J Gastroenterol; 2004 Aug; 99(8):1437-41. PubMed ID: 15307856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heartburn severity does not predict disease severity in patients with erosive esophagitis.
    Fennerty MB; Johnson DA
    MedGenMed; 2006 Apr; 8(2):6. PubMed ID: 16926745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.
    Robinson M; Lanza F; Avner D; Haber M
    Ann Intern Med; 1996 May; 124(10):859-67. PubMed ID: 8610914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
    Adachi K; Hashimoto T; Hamamoto N; Hirakawa K; Niigaki M; Miyake T; Taniura H; Ono M; Kaji T; Suetsugu H; Yagi J; Komazawa Y; Mihara T; Katsube T; Fujishiro H; Shizuku T; Hattori S; Yamamoto S; Kinoshita Y
    J Gastroenterol Hepatol; 2003 Dec; 18(12):1392-8. PubMed ID: 14675268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
    Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
    Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
    Zhang W; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
    Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
    Oshima T; Igarashi A; Nakano H; Deguchi H; Fujimori I; Fernandez J
    J Clin Gastroenterol; 2022 Jul; 56(6):493-504. PubMed ID: 35470298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term clinical outcome of elderly patients with reflux esophagitis: a six-month to three-year follow-up study.
    Pilotto A; Franceschi M; Leandro G; Novello R; Di Mario F; Valerio G
    Am J Ther; 2002; 9(4):295-300. PubMed ID: 12115018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
    Behm BW; Peura DA
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
    Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
    Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
    Vaezi MF; Fass R; Vakil N; Reasner DS; Mittleman RS; Hall M; Shao JZ; Chen Y; Lane L; Gates AM; Currie MG
    Gastroenterology; 2020 Jun; 158(8):2093-2103. PubMed ID: 32092310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.